

STATUTORY INSTRUMENTS

2009 No. 3136

**The Misuse of Drugs (Amendment) (England,
Wales and Scotland) Regulations 2009**

Amendment to the 2001 Regulations

4.—(1) In Schedule 1 (which specifies controlled drugs subject to the requirements of regulations 14, 15, 16, 18, 19, 20, 23, 26 and 27)—

(a) in paragraph 1(a)—

(i) after “Concentrate of poppy-straw”, insert—

“[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1, 2, 3-*de*]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone
3-Dimethylheptyl-11-hydroxyhexahydrocannabinol”;

(ii) after “Fungus (of any kind) which contains psilocin or an ester of psilocin”, insert—

“[9-Hydroxy-6-methyl-3-[5-phenylpentan-2-yl] oxy-5, 6, 6a, 7, 8, 9, 10, 10a-octahydrophenanthridin-1-yl] acetate
9-(Hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a, 7, 10, 10a-tetrahydrobenzo[*c*]chromen-1-ol”;

(b) after paragraph 1(f), insert—

“(g) 1-benzylpiperazine or any compound (not being a compound for the time being specified in Schedule 4) structurally derived from 1-benzylpiperazine or 1-phenylpiperazine by modification in any of the following ways—

(i) by substitution at the second nitrogen atom of the piperazine ring with alkyl, benzyl, haloalkyl or phenyl groups;

(ii) by substitution in the aromatic ring to any extent with alkyl, alkoxy, alkylendioxy, halide or haloalkyl groups;

(h) any compound structurally derived from 3-(1-naphthoyl)indole or 1*H*-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent;

(i) any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent;

(j) any compound structurally derived from 1-(1-naphthylmethyl)indene by substitution at the 3-position of the indene ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent;

- (k) any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent;
- (l) any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the cyclohexyl ring to any extent.”

(2) In paragraph 1 of Schedule 2 (which specifies controlled drugs subject to the requirements of regulations 14, 15, 16, 18, 19, 20, 21, 23, 26 and 27)—

- (a) after “Myrophine”, insert “Nabilone”;
- (b) after “Norpipanone”, insert “Oripavine”.

(3) In paragraph 1 of Part 1 of Schedule 4 (which specifies controlled drugs subject to the requirements of regulations 22, 23, 26 and 27), after “Chlordiazepoxide”, insert—

“1-(3-chlorophenyl)piperazine
1-(3-chlorophenyl)-4-(3-chloropropyl)piperazine”.

(4) In Part 2 of Schedule 4 (controlled drugs excepted from the prohibition on possession when in the form of a medicinal product)—

- (a) in paragraph 1—
 - (i) before “4-Androstene-3,17-dione”, insert—
“5 α -Androstane-3,17-diol
Androst-4-ene-3,17-diol
1-Androstenediol
1-Androstenedione”;
 - (ii) after “4-Androstene-3,17-dione”, insert “5-Androstenedione”;
 - (iii) after “Boldenone”, insert “Boldione”;
 - (iv) after “Clostebol”, insert—
“Danazol
Desoxymethyltestosterone”;
 - (v) after “Furazabol”, insert—
“Gestrinone
3-Hydroxy-5 α -androstan-17-one”;
 - (vi) after “Nandrolone”, insert “19-Norandrostenedione”;
 - (vii) after “19-Nor-5-Androstene-3,17-diol”, insert “19-Norandrosterone”;
 - (viii) after “Norethandrolone”, insert “19-Noretiocholanolone”;
 - (ix) after “Propetandrol”, insert “Prostanazol”;
 - (x) after “Testosterone”, insert “Tetrahydrogestrinone”;
- (b) in paragraph 4, after “Somatropin”, insert—
“Zeranol
Zilpaterol”.